Invasive fungal infections remain dangerously underserved, underscoring the urgent demand for antifungal therapies that can meet today’s clinical challenges. Systemic fungal infections are a growing global health threat, causing over 6.5 million cases and 3.8 million deaths annually. Current treatment options often fall short due to rising resistance, toxicity, and limited effectiveness in severe infections such as pulmonary fungal infections (PFIs).

In 2024, the systemic antifungal treatment market was valued at $11.9 billion and is projected to reach over $36 billion by 2035, driven by increasing incidence and demand for safer, more effective therapies.

Our novel liposomal formulation of mupirocin is designed to target a broad spectrum of fungal pathogens including yeasts, molds, and dimorphic fungi. Optimized for safety and efficacy, our innovative approach holds promise for treating even the most challenging fungal infections with precision and power.

Invasive fungal infections remain dangerously underserved, underscoring the urgent demand for antifungal therapies that can meet today’s clinical challenges. Systemic fungal infections are a growing global health threat, causing over 6.5 million cases and 3.8 million deaths annually. Current treatment options often fall short due to rising resistance, toxicity, and limited effectiveness in severe infections such as pulmonary fungal infections (PFIs).

In 2024, the systemic antifungal treatment market was valued at $11.9 billion and is projected to reach over $36 billion by 2035, driven by increasing incidence and demand for safer, more effective therapies.

Our novel liposomal formulation of mupirocin is designed to target a broad spectrum of fungal pathogens including yeasts, molds, and dimorphic fungi. Optimized for safety and efficacy, our innovative approach holds promise for treating even the most challenging fungal infections with precision and power.

Candida Albicans